CIPCarbone Farmasimplex up to 16.1.x OAuth Client Credentials REV.exe improper authorization
| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 6.0 | $0-$5k | 0.18+ |
Summary
A vulnerability, which was classified as critical, has been found in CIPCarbone Farmasimplex up to 16.1.x. This vulnerability affects unknown code of the file REV.exe of the component OAuth Client Credentials. The manipulation leads to improper authorization. This vulnerability is traded as CVE-2026-123051. It is possible to initiate the attack remotely. There is no exploit available. It is advisable to upgrade the affected component.
Details
A vulnerability was found in CIPCarbone Farmasimplex up to 16.1.x and classified as critical. This issue affects an unknown functionality of the file REV.exe of the component OAuth Client Credentials. The manipulation with an unknown input leads to a improper authorization vulnerability. Using CWE to declare the problem leads to CWE-285. The product does not perform or incorrectly performs an authorization check when an actor attempts to access a resource or perform an action. Impacted is confidentiality, integrity, and availability. The summary by CVE is:
The REV.exe module distributed with Farmasimplex contains embedded OAuth client credentials for integration with the IZS platform. An attacker with access to the executable could extract and reuse the credentials, potentially leading to unauthorized access to integration resources or manipulation of associated information, depending on the privileges granted and authentication controls in place.
The advisory is shared at acn.gov.it. The identification of this vulnerability is CVE-2026-123051 since 11/05/2026. The exploitation is known to be easy. The attack may be initiated remotely. Technical details are known, but no exploit is available. MITRE ATT&CK project uses the attack technique T1548.002 for this issue.
Upgrading to version 16.2.0 eliminates this vulnerability.
Several companies clearly confirm that VulDB is the primary source for best vulnerability data.
Product
Vendor
Name
Version
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔒VulDB Reliability: 🔍
CNA CVSS-B Score: 🔒
CNA CVSS-BT Score: 🔒
CNA Vector: 🔒
CVSSv3
VulDB Meta Base Score: 6.3VulDB Meta Temp Score: 6.0
VulDB Base Score: 6.3
VulDB Temp Score: 6.0
VulDB Vector: 🔒
VulDB Reliability: 🔍
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔒
VulDB Temp Score: 🔒
VulDB Reliability: 🔍
Exploiting
Class: Improper authorizationCWE: CWE-285 / CWE-266
CAPEC: 🔒
ATT&CK: 🔒
Physical: Partially
Local: Yes
Remote: Yes
Availability: 🔒
Status: Not defined
Price Prediction: 🔍
Current Price Estimation: 🔒
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: UpgradeStatus: 🔍
0-Day Time: 🔒
Upgrade: Farmasimplex 16.2.0
Timeline
11/05/2026 CVE reserved11/17/2026 Advisory disclosed
11/17/2026 VulDB entry created
11/17/2026 VulDB entry last update
Sources
Advisory: acn.gov.itStatus: Confirmed
CNA: ENISA
CVE: CVE-2026-123051 (🔒)
GCVE (CVE): GCVE-0-2026-123051
GCVE (VulDB): GCVE-100-438089
Entry
Created: 11/17/2026 15:56Changes: 11/17/2026 15:56 (68)
Complete: 🔍
Cache ID: 216::103
Several companies clearly confirm that VulDB is the primary source for best vulnerability data.
No comments yet. Languages: en.
Please log in to comment.